



Supplementary Figure 5: A. Quantification of phospho-p65 (NF- κ b) staining in MOC2 and mEERL WT/KO-Gal1 tumors (N=5 tumors, 3 random microscopic fields per tumor). **B.** Quantitation of STING mRNA levels in MOC2 and mEERL WT/KO-Gal1 cell lines. **C.** Immunoblot showing degradation kinetics of STING in LLC and FaDu WT/KD-Gal1 cells at 1, 2, 4h post cycloheximide treatment. **D.** Magnified images showing co-localization of STING and LAMP1 in MOC2 WT/KO-Gal1 cells. **E.** Representative images showing low and high IHC staining of STING in oral cavity cancer (Left) and the distribution of negative and positive STING staining in 83 oral cavity cancers on the TMA. **F.** Kaplan Meier curve showing progression-free survival (calculated as the time from the surgery date until death or progression) of patients based on Gal1 and STING expression in the tumor.